Survival Outcomes and Care Equity among Patients with Advanced Breast Cancer in Auckland, New Zealand

Table 2

Key survival outcomes.

Parameter	Subgroups		medOS(LQ-UQ) in months
Relapsed versus De novo	rMBC	270	18.7 (7.0-39.1)
	dnMBC	118	18.9 (9.2-41.7)
Receptor subtypes	ER + PR + HER2-	202	26.9 (11.4-44.7)
	ER + PR-HER2-	35	22.4 (8.9-39.3)
	ER-PR- HER2+	31	13.8 (3.6-33.1)
	ER + PR + HER2+	33	20.8 (13.2-44.8)
	Triple negative	73	10.6 (3.9-18.7)
Ethnicity	European	232	18.9 (7.4-39.4)
	Māori	35	16.2 (7.0-38.9)
	Asian	50	26.3 (10.8-46.8)
	Pacific peoples	66	17.3 (6.9-39.0)
No. of lines of treatment	None	53	3.3 (1.6-9.6)
	1	111	9.7 (4.7-31.7)
	2-3	145	20.8 (14.4-41.2)
	4-5	57	32.4 (25.3-43.8)
	6+	21	47.6 (32-59.1)